Children at a community health event in Timor Leste, one of the locations where Health Alliance International has maternal-child health programs. Photo credit: Jessica Dyer (MPH '15), George Povey Fellow.

Connect: Global Health Resource Center

Enter a keyword to search

Interactive World Map

Discover our impact all over the world.

Numbers displayed on the map are a representation of the activity in each country. Once you use the filter selections below, you will have the opportunity to explore projects and faculty in each country.

Overview

Filter from the selections below

HVTN 108: A phase 1/2a clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA, and of MF59®- or AS01B-adjuvanted clade C Env protein in various combinations, in healthy, HIV-uninfected adult participants

The HVTN 108 trial is designed primarily to: Evaluate the safety and tolerability of DNA and/or different doses of clade C bivalent gp120 protein with either MF59 or AS01B adjuvant in various regimens in HIV uninfected healthy adults; and evaluate the systemic immune responses at the Month 6.5 timepoint (2 weeks after the 4th vaccination) of clade C DNA, bivalent gp120 protein/MF59, and/or bivalent gp120 protein/AS01B in each vaccine regimen. Funding is provided by HIV Vaccine Trials Network